Skip to content
value.today

Kala Pharmaceuticals, Inc.

Total raised
$115 M
7 rounds on record
Latest round
$68 M
Apr 2016
First round on record
Dec 2009
Today
Went public
See the company page

Kala Pharmaceuticals, Inc. is listed today as Kala Pharmaceuticals: market value, financials and filings are on its company page.

Funding rounds

7 counted as startup funding, 5 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Kala Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2026$2 MPrivate placement after listingUnder $2 million

Kala Pharmaceuticals, Inc.: Private sale, Mar 2026

Investors in this round

1 investor had bought by the notice of Mar 17, 2026: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
$1,753,500
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Avi Minkowitz · Executive Officer, Director
  • Brendan Purdy · Director
  • Chaim Berger · Director
  • Hillel Posen · Director
  • Yonatan Colman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total offering amount is based off the closing price of KALA BIO, Inc.'s common stock on March 3, 2026 ($0.3507) for 5 million shares of common stock being issued.”

Signed by Avi Minkowitz, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 17, 2026. Read the notice at the SEC.

equitySEC
Jan 2026$2 MPrivate placement after listing$2 to $10 million

Kala Pharmaceuticals, Inc.: Private sale, Jan 2026

Investors in this round

20 investors had bought by the notice of Feb 13, 2026: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $4 M offered; $2 M still to sell
Smallest investment taken
$44,905
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$38,988
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Avi Minkowitz · Executive Officer, Director · Chief Executive Officer, Chief Financial Officer and Director
  • Brendan Purdy · Director · Director
  • Chaim Berger · Director · Director
  • David Lazar · Director · Director
  • Hillel Posen · Director · Director
  • Yonatan Colman · Director · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • FM Global Markets Inc. (CRD 000174843) · Toronto, Canada (Federal Level)Sold in CO, DE, FL, NY, WY, and outside the US

Remarks in the notice

  • On the amounts: “The issuer issued 1,125,300 shares of Series AAA Preferred Stock at $2.00 per share for aggregate proceeds of $2,250,600 in a private placement pursuant to Rule 506(b) of Reg. D and 974,700 shares pursuant to Rule 903 of Reg. S.”

Signed by Avi Minkowitz, CEO, CFO and Director. Source: SEC Form D, newest notice filed Feb 13, 2026. Read the notice at the SEC.

equitySEC
Dec 2024$11 MPrivate placement after listing$10 to $50 million

Kala Pharmaceuticals, Inc.: Private sale, Dec 2024

Investors in this round

6 investors had bought by the notice of Dec 31, 2024: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Darius Kharabi · Executive Officer
  • Kim Brazzell · Executive Officer
  • Mark Iwicki · Executive Officer, Director
  • Mary Reumuth · Executive Officer
  • Todd Bazemore · Executive Officer
  • Andrew I. Koven · Director
  • C. Daniel Myers · Director
  • Gregory D. Perry · Director
  • Howard B. Rosen · Director
  • Marjan D. Farid · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mary Reumuth, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 31, 2024. Read the notice at the SEC.

equitySEC
Jun 2024$13 MPrivate placement after listing$10 to $50 million

Kala Pharmaceuticals, Inc.: Private sale, Jun 2024

Investors in this round

5 investors had bought by the notice of Jun 28, 2024: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$13 M of $13 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Darius Kharabi · Executive Officer
  • Kim Brazzell · Executive Officer
  • Mark Iwicki · Executive Officer, Director
  • Mary Reumuth · Executive Officer
  • Todd Bazemore · Executive Officer
  • Andrew I. Koven · Director
  • C. Daniel Myers · Director
  • Gregory D. Perry · Director
  • Howard B. Rosen · Director
  • Marjan D. Farid · Director
  • Mark S. Blumenkranz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mary Reumuth, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 28, 2024. Read the notice at the SEC.

equitySEC
Nov 2021$16 MPrivate placement after listing$10 to $50 million

Kala Pharmaceuticals, Inc.: Private sale, Nov 2021

Investors in this round

26 investors had bought by the notice of Nov 29, 2021: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$16 M of $37 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Darius Daniel Kharabi · Executive Officer
  • Eric L. Trachtenberg · Executive Officer
  • Hongming Chen · Executive Officer
  • Kim Brazzell · Executive Officer
  • Mark Iwicki · Executive Officer, Director
  • Mary Reumuth · Executive Officer
  • Todd Bazemore · Executive Officer
  • Andrew L. Koven · Director
  • C. Daniel Myers · Director
  • Gregory D. Grunberg · Director
  • Gregory D. Perry · Director
  • Howard B. Rosen · Director
  • Mark S. Blumenkranz · Director
  • Robert D. Paull · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total offering amount includes up to $20.4 million of shares of common stock that may be issued by the Issuer upon the achievement of specified milestones. The total amount sold includes $2,015,224 of shares subject to a post-closing holdback.”

Signed by Mary Reumuth, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 29, 2021. Read the notice at the SEC.

equitySEC
Apr 2016$68 MNo. 7$50 to $250 million

Kala Pharmaceuticals, Inc.: Raise no. 7, Apr 2016

Investors in this round

25 investors had bought by the notice of Apr 13, 2016: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$68 M of $68 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles B. McDermott · Executive Officer
  • Hongming B. Chen · Executive Officer
  • Kim Brazzell · Executive Officer
  • Mark Iwicki · Executive Officer, Director
  • Chen B. Yu · Director
  • Greg Grunberg · Director
  • Howard B. Rosen · Director
  • Kevin Bitterman · Director
  • Rajeev B. Shah · Director
  • Robert Langer · Director
  • Robert Paull · Director
  • Robert Tepper · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark Iwicki, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 13, 2016. Read the notice at the SEC.

equitySEC
Aug 2015$7 MNo. 6$2 to $10 million

Kala Pharmaceuticals, Inc.: Raise no. 6, Aug 2015

Investors in this round

1 investor had bought by the notice of Aug 19, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles B. McDermott · Executive Officer
  • Hongming B. Chen · Executive Officer
  • Kim Brazzell · Executive Officer
  • Mark Iwicki · Executive Officer, Director
  • Howard B. Rosen · Director
  • Karen Wagner · Director
  • Kevin Bitterman · Director
  • Rajeev B. Shah · Director
  • Robert Langer · Director
  • Robert Paull · Director
  • Robert Tepper · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Charles McDermott, President. Source: SEC Form D, newest notice filed Aug 19, 2015. Read the notice at the SEC.

equitySEC
Apr 2014$23 MNo. 5$10 to $50 million

Kala Pharmaceuticals, Inc.: Raise no. 5, Apr 2014

Investors in this round

16 investors had bought by the notice of Apr 24, 2014: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$23 M of $23 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Guillaume Pfefer · Executive Officer, Director
  • Kim Brazzell · Executive Officer
  • Bernard Gilly · Director
  • Howard B. Rosen · Director
  • Kevin Bitterman · Director
  • Robert Langer · Director
  • Robert Paull · Director
  • Robert Tepper · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Guillaume Pfefer, President and CEO. Source: SEC Form D, newest notice filed Apr 24, 2014. Read the notice at the SEC.

equitySEC
Feb 2013$6 MNo. 4$2 to $10 million

Kala Pharmaceuticals, Inc.: Raise no. 4, Feb 2013

Investors in this round

10 investors had bought by the notice of Feb 28, 2013: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $12 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrea Franz · Executive Officer
  • Guillaume Pfefer · Executive Officer, Director
  • Bernard Gilly · Director
  • Kevin Bitterman · Director
  • Robert Langer · Director
  • Robert Paull · Director
  • Robert Tepper · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrea Franz, Treasurer and Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 28, 2013. Read the notice at the SEC.

equitySEC
Feb 2012$7 MNo. 3$2 to $10 million

Kala Pharmaceuticals, Inc.: Raise no. 3, Feb 2012

Investors in this round

10 investors had bought by the notice of Mar 14, 2012: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Hongming Chen · Executive Officer
  • Kevin Pojasek · Executive Officer
  • Peter Courossi · Executive Officer
  • Robert Paull · Executive Officer, Director
  • Justin Hanes · Director
  • Kevin Bitterman · Director
  • Robert Langer · Director
  • Robert Tepper · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kevin Pojasek, Secretary and Vice President, Corporate Development. Source: SEC Form D, newest notice filed Mar 14, 2012. Read the notice at the SEC.

equitySEC
Oct 2010$3 MNo. 2$2 to $10 million

Kala Pharmaceuticals, Inc.: Raise no. 2, Oct 2010

Investors in this round

9 investors had bought by the notice of Nov 10, 2010: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Robert Paull · Executive Officer, Director
  • Justin Hanes · Director
  • Kevin Bitterman · Director
  • Robert Langer · Director
  • Robert Tepper · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert Paull, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 10, 2010. Read the notice at the SEC.

equity, debtSEC
Dec 2009$2 MNo. 1$2 to $10 million

Kala Pharmaceuticals, Inc.: Raise no. 1, Dec 2009

Investors in this round

10 investors had bought by the notice of Dec 23, 2009: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Kala Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Robert Paull · Executive Officer, Director, Promoter
  • Justin Hanes · Director
  • Robert Langer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert Paull, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 23, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Kala Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2026).

    SEC Form D · Mar 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2026

That is all the official record says: Kala Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Kala Pharmaceuticals, Inc. are on record.

Investors#

23 named in official filings. Open an investor to see everything it has backed.

Investors in Kala Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Baker Bros. Advisors (GP) LLCFund or asset managernot statednot statedHeld Series E, F, G and H preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Baker Bros. Advisors LPFund or asset managernot statednot statedHeld Series E, F, G and H preferred stock, 10% owner (Form 3, 2024)SEC Form 3
BioFund I. Fcr YsiosPersonnot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Caxton CorpCompanynot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
CDK Associates, L.L.C.Othernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
CVF LLCOthernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Hadley Harbor Master Investors (Cayman) L.P.Fund or asset managernot statednot statedHeld Series B-1 and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Longitude Capital Partners II, LLCFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Longitude Venture Partners II, L.P.Venture capitalnot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Lux Capital Management, LLCFund or asset managernot statednot statedHeld Series Seed, A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Lux Venture Associates II, LLCVenture capitalnot statednot statedHeld Series Seed, A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Lux Venture Partners II, L.P.Venture capitalnot statednot statedHeld Series Seed, A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Lux Ventures II, L.P.Venture capitalnot statednot statedHeld Series Seed, A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Lux Ventures II Sidecar LPVenture capitalnot statednot statedHeld Series Seed, A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
OrbiMed Capital GP VI LLCFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Polaris Venture Management Co. V, L.L.C.Venture capitalnot statednot statedHeld Series Seed, A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Polaris Venture Partners Entrepreneurs' Fund V, L.P.Venture capitalnot statednot statedHeld Series Seed, A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Polaris Venture Partners Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series Seed, A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Polaris Venture Partners Special Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series Seed, A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Polaris Venture Partners V, L.P.Venture capitalnot statednot statedHeld Series Seed, A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
RA Capital Healthcare Fund LPFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Ra Capital Management, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner, director (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 25 investors.

Largest shareholders today

Institutions holding Kala Pharmaceuticals shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Kala Pharmaceuticals, Inc.
NameRoleNamed in
Avi MinkowitzExecutive officerMar 2026
Darius KharabiExecutive officerDec 2024
Kim BrazzellExecutive officerDec 2024
Mark IwickiExecutive officerDec 2024
Mary ReumuthExecutive officerDec 2024
Todd BazemoreExecutive officerDec 2024
Darius Daniel KharabiExecutive officerNov 2021
Eric L. TrachtenbergExecutive officerNov 2021
Hongming ChenExecutive officerNov 2021
Charles B. McDermottExecutive officerApr 2016
Hongming B. ChenExecutive officerApr 2016
Guillaume PfeferExecutive officerApr 2014
Andrea FranzExecutive officerFeb 2013
Kevin PojasekExecutive officerMar 2012
Peter CourossiExecutive officerMar 2012
Robert PaullExecutive officerMar 2012
Avi MinkowitzDirectorMar 2026
Brendan PurdyDirectorMar 2026
Chaim BergerDirectorMar 2026
Hillel PosenDirectorMar 2026
Yonatan ColmanDirectorMar 2026
David LazarDirectorFeb 2026
Andrew I. KovenDirectorDec 2024
C. Daniel MyersDirectorDec 2024
Gregory D. PerryDirectorDec 2024
Howard B. RosenDirectorDec 2024
Marjan D. FaridDirectorDec 2024
Mark IwickiDirectorDec 2024
Mark S. BlumenkranzDirectorJun 2024
Andrew L. KovenDirectorNov 2021
Gregory D. GrunbergDirectorNov 2021
Robert D. PaullDirectorNov 2021
Chen B. YuDirectorApr 2016
Greg GrunbergDirectorApr 2016
Kevin BittermanDirectorApr 2016
Rajeev B. ShahDirectorApr 2016
Robert LangerDirectorApr 2016
Robert PaullDirectorApr 2016
Robert TepperDirectorApr 2016
Karen WagnerDirectorAug 2015

About

Company in Waltham, United States.

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.